HeartBeam (NASDAQ:BEAT) Director Marga Ortigas-Wedekind Purchases 25,000 Shares

April 17, 2026 by InsiderTrades.com

Key Points

Director Mark E. Strome purchased 750,000 shares at an average price of $0.80 on April 16th (a $600,000 transaction), bringing his holdings to 3,650,000 shares — a 25.86% increase that signals insider confidence.
HeartBeam priced and closed a $10 million public offering to fund commercialization and AI initiatives, a dilutive event that coincided with a post‑offering share price dip while reported short interest fell ~22.8%, reducing immediate short‑selling pressure.
The company has a small market cap (~$33.3 million), negative trailing EPS, and a low share price (opened $0.81) but carries a consensus analyst target of about $4.80, reflecting mixed sentiment and high volatility risk.

HeartBeam, Inc. (NASDAQ:BEAT - Get Free Report) Director Marga Ortigas-Wedekind bought 25,000 shares of the business's stock in a transaction that occurred on Thursday, April 16th. The stock was purchased at an average price of $0.80 per share, with a total value of $20,000.00. Following the completion of the purchase, the director directly owned 137,293 shares in the company, valued at $109,834.40. The trade was a 22.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

HeartBeam Stock Down 8.5%

Shares of NASDAQ BEAT opened at $0.81 on Friday. HeartBeam, Inc. has a twelve month low of $0.54 and a twelve month high of $4.00. The company has a market cap of $33.28 million, a PE ratio of -1.31 and a beta of -0.63. The business's 50 day moving average price is $1.30 and its two-hundred day moving average price is $1.62.

HeartBeam (NASDAQ:BEAT - Get Free Report) last issued its earnings results on Thursday, March 12th. The medical research company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01).

Analyst Ratings Changes

BEAT has been the topic of several research analyst reports. Weiss Ratings reissued a "sell (e+)" rating on shares of HeartBeam in a report on Monday, December 29th. D. Boral Capital assumed coverage on HeartBeam in a report on Friday, March 27th. They set a "buy" rating and a $5.00 price target for the company. Wall Street Zen downgraded HeartBeam to a "strong sell" rating in a research note on Saturday, January 3rd. HC Wainwright reiterated a "buy" rating and set a $5.50 price objective on shares of HeartBeam in a research report on Monday, March 16th. Finally, B. Riley Financial initiated coverage on shares of HeartBeam in a research report on Tuesday, March 31st. They issued a "buy" rating and a $4.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, HeartBeam has an average rating of "Moderate Buy" and a consensus price target of $4.80.

Get Our Latest Stock Analysis on BEAT

Institutional Investors Weigh In On HeartBeam

Hedge funds and other institutional investors have recently made changes to their positions in the business. Raymond James Financial Inc. boosted its stake in shares of HeartBeam by 102.2% in the second quarter. Raymond James Financial Inc. now owns 28,178 shares of the medical research company's stock valued at $35,000 after buying an additional 14,242 shares during the period. Bessemer Group Inc. bought a new position in HeartBeam during the 3rd quarter worth $25,000. Kestra Private Wealth Services LLC increased its stake in HeartBeam by 23.4% during the 3rd quarter. Kestra Private Wealth Services LLC now owns 175,989 shares of the medical research company's stock worth $290,000 after acquiring an additional 33,344 shares during the period. Ritholtz Wealth Management raised its holdings in HeartBeam by 49.6% in the 4th quarter. Ritholtz Wealth Management now owns 208,191 shares of the medical research company's stock valued at $500,000 after acquiring an additional 69,009 shares in the last quarter. Finally, Spectrum Asset Management Inc. NB CA lifted its position in shares of HeartBeam by 26.9% during the 4th quarter. Spectrum Asset Management Inc. NB CA now owns 94,400 shares of the medical research company's stock valued at $227,000 after acquiring an additional 20,000 shares during the period. 7.77% of the stock is currently owned by institutional investors and hedge funds.

HeartBeam News Summary

Here are the key news stories impacting HeartBeam this week:

Positive Sentiment: Senior insiders (multiple directors and the CFO) purchased a total of ~1.12M shares at $0.80 apiece (roughly $895k in aggregate), including a 750k‑share buy by director Mark E. Strome, signaling management confidence and increasing insider ownership. SEC Filing — Mark E. Strome
Positive Sentiment: Reported short interest fell ~22.8%, which reduces immediate short‑selling pressure and can support the share price during this post‑offering period. Short interest report
Neutral Sentiment: Recent analyst/press comparison pieces examine HeartBeam versus peers; useful for longer‑term competitive/contextual perspective but not an immediate catalyst. Competitive comparison
Negative Sentiment: HeartBeam launched and priced a $10 million public offering to support commercialization and AI initiatives. Equity offerings are dilutive and typically weigh on the share price; media coverage noted the stock slipped after the offering was priced. Offering pricing Offering closing Market reaction article

HeartBeam Company Profile

(Get Free Report)

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.